orphan-disease-opportunity-mcp
Provides an OpenAPI 3.1 specification compatible with LangChain's OpenAPIToolkit for querying rare-disease opportunity data over HTTPS.
Provides an OpenAPI 3.1 specification that can be imported into OpenAI Custom GPT Actions to query the rare-disease opportunity dataset over HTTPS without backend infrastructure.
Click on "Deploy Server".
Wait a few minutes for the server to deploy. Once ready, it will show a "Started" state.
In the chat, type
@followed by the MCP server name and your instructions, e.g., "@orphan-disease-opportunity-mcp Find bootstrapped, no-wet-lab opportunities in jak2-myelofibrosis"
That's it! The server will respond to your query, and you can continue using it as needed.
Here is a step-by-step guide with screenshots.
orphan-disease-opportunity-mcp
Open Venture & Translational Opportunity Atlas — Model Context Protocol (MCP) Server
Flagship Deep-Dive #1: JAK2 V617F Myelofibrosis (jak2-myelofibrosis) • Web Dossier: https://rare-disease-atlas.github.io
mcp-name: io.github.rare-disease-atlas/orphan-disease-opportunity-mcp
An open, zero-third-party-dependency Python MCP server and OpenAPI 3.1 toolkit designed for technical founders (Computational / AI-Bio, Public Health Systems, Venture / Novel Financing) and autonomous AI research agents evaluating high-tractability orphan disease startups, drug-repurposing wedges, non-dilutive SBIR/venture-philanthropy grants, and ethical clinical validation pathways.
Instant 1-Command Installation (Zero PyPI Wait Required)
Run directly from GitHub via uvx with zero external runtime dependencies (pure Python >= 3.10 standard library):
uvx --from git+https://github.com/rare-disease-atlas/orphan-disease-opportunity-mcp orphan-disease-opportunity-mcp(Once published to PyPI, uvx orphan-disease-opportunity-mcp also runs identically.)
Add to Claude Code (1 Command)
claude mcp add orphan-disease-opportunities -- uvx --from git+https://github.com/rare-disease-atlas/orphan-disease-opportunity-mcp orphan-disease-opportunity-mcpAdd to Claude Desktop / Cursor / Windsurf / Cline / Antigravity
Add to claude_desktop_config.json, .cursor/mcp.json, or your MCP client settings:
{
"mcpServers": {
"orphan-disease-opportunities": {
"command": "uvx",
"args": [
"--from",
"git+https://github.com/rare-disease-atlas/orphan-disease-opportunity-mcp",
"orphan-disease-opportunity-mcp"
]
}
}
}Related MCP server: Cofound Plugin
Why This Exists
Over 7,000 rare diseases carry FDA Orphan Drug Act structural advantages (7-year US market exclusivity, 100% waiver of the $4,682,003 FY2026 PDUFA filing fee, 25% qualified clinical trial tax credit, and N=120–350 pivotal trials), yet technical builders outside traditional wet-lab pharma rarely see where single-mutation structural tractability intersects urgent standard-of-care failure.
Flagship Case Study #1 (jak2-myelofibrosis) models this end-to-end:
Causal Precision: A single somatic mutation (
JAK2 V617Fin the JH2 pseudokinase autoinhibitory domain) drives ~50–60% of Primary Myelofibrosis (ORPHA:824, ~15,000–25,000 US patients).First-Gen SoC Failure Cliff: All 4 FDA-approved JAK inhibitors (ruxolitinib, fedratinib, pacritinib, momelotinib) are Type I ATP-competitive binders of the conserved JH1 catalytic domain, inhibiting wild-type JAK2 alongside V617F—causing dose-limiting anemia/thrombocytopenia, ~50% discontinuation within 3 years, minimal clonal eradication, and 11–23 month median survival post-ruxolitinib failure.
Zero-Wet-Lab & Low-Capital Wedges: Structure-guided JH2 V617F vs WT (
PDB: 4FVR/6E2Q/8BAK/8EX2vs4FVP) allosteric/PROTAC design + outsourced CRO screening; AI marrow fibrosis digital pathology (MF-0..3composite endpoints solving the Phase 3 SVR35/TSS50 crisis); single-cell megakaryocyte-stroma drug repurposing (GSE144568,GSE156644); no-washout RWE clinical trial matching; allo-HSCT timing CDS; and evergreen venture-philanthropy SPVs.
Exposed MCP Capabilities
Tools (tools/list & tools/call)
Tool | Parameters | Capability |
|
| Filters startup & translational blueprints with unit economics, regulatory pathways, open datasets, and 90-day milestones. Syncs live from |
|
| Returns causal JH2 vs JH1 biology, Type I JAKi failure modes, FDA Orphan Drug economics, $1.7B–$2.9B M&A comps, and open |
|
| Maps NCI/NHLBI SBIR, MPN Research Foundation ( |
|
| Maps institutional registries ( |
Resource (resources/read)
briefing://rare-disease-playbook/jak2-myelofibrosis— Complete Markdown venture & translational playbook.
Prompt (prompts/get)
evaluate-rare-disease-venture— Multi-step 90-day killer-experiment, non-dilutive grant-stacking, and ethical validation workflow (founder_background,capital_budget,wet_lab_access).
Alternative Deployment Modes
Docker (Hardened Non-Root Container)
docker build -t orphan-disease-opportunity-mcp .
# Stdio MCP transport
docker run -i --rm orphan-disease-opportunity-mcp
# Remote Streamable HTTP MCP server (exposes POST /mcp, GET /.well-known/mcp.json, GET /health)
docker run --rm -p 8080:8080 orphan-disease-opportunity-mcp --transport http --host 0.0.0.0 --port 8080Local Source Execution
git clone https://github.com/rare-disease-atlas/orphan-disease-opportunity-mcp.git
cd orphan-disease-opportunity-mcp
python3 -m orphan_disease_mcpCustom GPT Actions & OpenAPI 3.1 Agents
Import openapi.yaml directly into OpenAI Custom GPT Actions, LangChain OpenAPIToolkit, or any OpenAPI 3.1 client to query https://rare-disease-atlas.github.io/opportunities.json over HTTPS with zero backend infrastructure.
Environment Variables (Optional)
Variable | Default | Description |
|
| Override URL for live JSON dataset sync. |
| unset ( | Set to |
Verification & Quality Assurance
Run the full zero-dependency end-to-end test suite (covers stdio JSON-RPC 2.0 lifecycle, all 4 tools, live HTTP mock sync + offline fallback, Streamable HTTP transport, and server.json / glama.json / smithery.yaml / openapi.yaml schema checks):
python3 test_mcp.pyLicense
MCP Server Code: MIT License (
Copyright (c) 2026 Rare Disease Venture Atlas)Opportunity & Case-Study Dataset (
opportunities.json): Creative Commons Attribution 4.0 International (CC-BY-4.0)
Available Tools
5 toolsfind_non_dilutive_grantsBInspect
Find non-dilutive SBIR/STTR, rare-disease foundation (MPNRF, Harrington), venture philanthropy (LLS TAP), FDA Orphan Products, and ARPA-H funding pathways.
Inputs: track.
get_disease_case_studyBInspect
Retrieve biological tractability, standard-of-care failure modes (e.g. Type I JH1 JAK inhibitor cytopenias vs JH2 V617F mutant selectivity), FDA Orphan Drug Act unit economics, and open structural/transcriptomic datasets for an orphan indication.
Inputs: disease_id.
get_validation_communitiesCInspect
Return established rare-disease patient & hematology clinical networks plus strict non-extractive ethical guidelines for founder problem discovery.
Inputs: disease_id.
match_founder_opportunitiesAInspect
Match high-tractability orphan disease startup & translational research blueprints by founder background, capital tier, and wet-lab requirement. Fetches live from rare-disease-atlas.github.io with bundled local fallback (Flagship Deep-Dive #1: JAK2 V617F Myelofibrosis).
Inputs: background, capital_tier, wet_lab_required.
submit_atlas_feedbackAInspect
Opt-in feedback & gap-reporting channel for AI agents and builders. Report missing founder wedges, requested orphan indications, new datasets, or ClinicalTrials.gov citation errata. Strictly exclude all personal identifiers (PII), patient health records, and confidential user IP.
Inputs: summary (required), disease_id, signal_type, agent_client, +1 more.
Tool Schema Changelog
Recent tool additions, removals, and schema changes observed during successful MCP inspections.
Loading tool schema changelog…
TDQS
Scored across 5 tools
Each tool targets a clearly distinct step in orphan-disease opportunity discovery: matching founders, retrieving disease case studies, finding grants, identifying validation communities, and submitting feedback. There is no meaningful overlap between the tools, and the descriptions make their boundaries explicit.
All tool names use consistent snake_case with a clear verb_object pattern such as match_founder_opportunities, get_disease_case_study, and find_non_dilutive_grants. The naming is predictable and readable throughout.
Five tools is well-scoped for this specialized workflow and each tool maps to a distinct need in the founder opportunity discovery process. None of the tools feels redundant or extraneous.
The surface covers the core lifecycle: opportunity matching, disease diligence, funding search, community validation, and feedback. Minor gaps remain, such as no explicit broad disease/opportunity search or deeper founder-blueprint retrieval separate from the matching tool, but agents can work around these through the existing tools.
Maintenance
Related MCP Connectors
MCP-native co-founder directory your AI agent searches, screening inbound pitches for you.
AI research on companies and industries — one MCP tool per research domain.
Find the right MCPs, tools and skills for any AI task - discovery over a 14k+ resource catalog.
Entity-resolved NIH grant corpus (FY1985-2026) via 14 read-only, provenance-carrying MCP tools.
Related MCP Servers
- FlicenseNot gradedqualityBmaintenanceConnects Claude or any MCP-compatible AI to a database of 960+ active VC funds for searching, fund profiles, live GP signals, and AI-powered startup-investor matching.1-

Cofound Pluginofficial
AlicenseNot gradedqualityDmaintenanceMCP-native co-founder directory. Your AI agent searches the directory, screens inbound pitches, and drafts replies.MIT- FlicenseNot gradedqualityDmaintenanceAI research on companies and industries — one MCP tool per research domain.-
- AlicenseNot gradedqualityFmaintenanceEnables AI agents to search verified collective knowledge, request and fulfill cognition bounties, and contribute to immune defense through MCP tools.8 npm1MIT